Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 27 for:    Saved Studies

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03404960
Recruitment Status : Recruiting
First Posted : January 19, 2018
Last Update Posted : February 25, 2019
Sponsor:
Collaborators:
Bristol-Myers Squibb
Tesaro, Inc.
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Drug: Niraparib + Nivolumab Drug: Niraparib + Ipilimumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy
Actual Study Start Date : January 31, 2018
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : June 2021


Arm Intervention/treatment
Experimental: Arm A
Niraparib + Nivolumab
Drug: Niraparib + Nivolumab
Niraparib 200mg PO daily on days 1-21 of each 21 day cycle Nivolumab 240mg IV days 1 and 15 of odd-numbered cycles; day 8 of even numbered cycles

Experimental: Arm B
Niraparib + Ipilimumab
Drug: Niraparib + Ipilimumab
Niraparib 200mg PO daily on days 1-21 of each 21 day cycle Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only




Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: 6 months after initiation of study therapy ]
    Progression-free survival at 6 months (PFS6) for both combinations according to RECIST v1.1, as assessed by the investigator


Secondary Outcome Measures :
  1. Proportion of tumors with homologous recombination deficits (HRD), in patients with stability or response to platinum therapy [ Time Frame: Cycle 1 Day 1 through completion of study treatment (maximum 42 months) ]
    Identification of HRDs and allele specific LOH via whole exome sequencing

  2. Objective response rate (ORR) in those with measurable disease [ Time Frame: From first restaging assessment through completion of study treatment (maximum 42 months) ]
    Measured by CT scans and other studies (MRI, X-ray, PET, and ultrasound)

  3. Duration of response (DOR) [ Time Frame: From first restaging assessment until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first ]
    Measured by CT scans and other studies (MRI, X-ray, PET, and ultrasound)

  4. Overall survival (OS) [ Time Frame: Cycle 1 Day 1 until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first ]
    start of treatment to death due to any cause or last patient contact alive

  5. Safety and tolerability of this combination. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03 [ Time Frame: From the initiation of any study intervention through 100 days (nivolumab patients) or 90 days (all patients) after patient End of Treatment Visit ]
    Safety based upon standard laboratory and clinical adverse event monitoring

  6. Correlation of HRDs with response to treatment with niraparib plus immune checkpoint blockade [ Time Frame: Cycle 1 Day 1 through completion of study treatment (maximum 42 months) ]
    Identification of HRDs and allele specific LOH via whole exome sequencing

  7. Immune activation prior to treatment [ Time Frame: Prior to initiation of study therapy (maximum 36 months) ]
    Assessed using immune biomarkers, and RNAseq of PBMC

  8. Immune activation prior during treatment [ Time Frame: Following receipt of study therapy and through study completion (maximum 42 months) ]
    Assessed using immune biomarkers, and RNAseq of PBMC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with locally advanced or metastatic disease
  2. Patients must be on treatment with platinum-based (cisplatin, oxaliplatin or carboplatin) treatment for locally advanced or metastatic pancreatic cancer and have received a minimum of 16 weeks of therapy without evidence of disease progression based on the investigator's opinion
  3. Patients may have previously failed non-platinum containing therapy or may never have previously progressed on treatment.

    -Discontinuation of the platinum component of the regimen for chemotherapy-related toxicity is permissible provided the patient has previously received at least 16 weeks of platinum-based therapy without evidence of disease progression ≤8 weeks after treatment with the platinum agent

  4. Measurable disease is not required for study entry
  5. Adequate organ function
  6. ECOG performance status of 0-1

Exclusion Criteria:

  1. Prior treatment with a PARP inhibitor, ipilimumab, nivolumab or other cytotoxic T-lymphocyte-associated protein (CTLA-4), PD-1 or PD-L1 inhibitor.
  2. Patients who have demonstrated resistance to platinum agents (e.g. oxaliplatin, cisplatin) are not eligible to participate in this study
  3. Clinical evidence of uncontrolled malabsorption and/or any other gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with the absorption of niraparib
  4. Received any systemic treatment for pancreatic cancer during the 14 days prior to first dose of treatment
  5. Acute infection requiring intravenous antibiotics, antiviral or antifungal agents during the 14 days prior to first dose of study therapy.
  6. Expected life expectancy of <12 weeks as determined by the investigator.
  7. Patients will be excluded if they have an active, known or suspected autoimmune disease, defined as: patients with a history of inflammatory bowel disease are excluded from this study, as are patients with a history of symptomatic autoimmune disease (eg rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis eg Wegener's Granulomatosis); motor neuropathy considered of autoimmune origin (eg Guillian-Barre Syndrome).

    NOTE: Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

  8. Has a history of interstitial lung disease or active, non-infectious pneumonitis
  9. Has received a live vaccine within 4 weeks prior to the first dose of trial therapy (Note: seasonal influenza vaccines for injection are generally inactivated and are allowed; however intranasal influenza vaccines (eg. Flu-Mist) are live attenuated vaccines and are not allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03404960


Contacts
Layout table for location contacts
Contact: Danielle Karlson 215-220-9704 danielle.karlson@uphs.upenn.edu

Locations
Layout table for location information
United States, Pennsylvania
University of Pennsylvania, Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Danielle Karlson    215-220-9704    danielle.Karlson@uphs.upenn.edu   
Principal Investigator: Kim Reiss Binder, MD         
Sponsors and Collaborators
University of Pennsylvania
Bristol-Myers Squibb
Tesaro, Inc.

Layout table for additonal information
Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03404960     History of Changes
Other Study ID Numbers: 828516
First Posted: January 19, 2018    Key Record Dates
Last Update Posted: February 25, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Pennsylvania:
Platinum
chemotherapy
Niraparib
Ipilimumab
Nivolumab
Pancreatic adenocarcinoma
PARP inhibitor
Pancreatic ductal adenocarcinoma
DDR
PDAC

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Nivolumab
Ipilimumab
Niraparib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action